好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Association Between Wearable Sensor Data and Clinical Scores in Individuals with Early-stage Multiple System Atrophy
Movement Disorders
P1 - Poster Session 1 (11:45 AM-12:45 PM)
5-026

We sought to determine the clinical meaningfulness of actigraphy metrics as they relate to typical motor symptoms of multiple system atrophy (MSA).

The symptomology of MSA, including parkinsonism, autonomic dysfunction, cerebellar symptoms, and pyramidal signs, reflects the disorder’s heterogeneity and challenges associated with diagnosis and disease monitoring. While traditional assessments are limited by a single clinic visit, digital at-home monitoring instruments overcome this disadvantage by allowing for continuous data collection. However, the value of wearable sensors in MSA has not been well defined.

We recruited 18 patients with clinically probable MSA and continuously monitored their physical activity using PAMSysTM sensors (BioSensics LLC, Newton, MA, USA) during a 12-month, 5-visit study. We applied Spearman’s rank correlations to determine associations between baseline clinical measures and sensor-derived parameters of posture, locomotion, and postural transitions over a one-week period. Additionally, we developed machine learning models to investigate the ability of sensor-derived measures to predict clinical scores.

Total walking time was negatively correlated with tandem walk (rho=-0.705) and Timed Up and Go (TUG) (rho=-0.811), while sedentary time was positively correlated with tandem walk (rho=0.626) and TUG (rho=0.597). We found a negative association between daily step count and walking episodes with tandem walk and TUG. Additionally, we identified positive relationships between average sit-to-stand and stand-to-sit durations with UMSARS-II (rho=0.722, 0.628), the motor section of NNIPPS-PPS (rho=0.690, 0.689), and TUG (rho=0.644, 0.596). Finally, regression models established successful prediction of clinical scores, with TUG demonstrating the highest explained variance.

These correlations suggest that sensor-derived metrics, specifically those measuring walking and postural transitions, may increase our understanding of impairments associated with MSA. Our results contribute meaningfulness to digital outcomes in MSA, underlining potential benefits sensors could hold for these patients. Additional longitudinal results will elucidate the value of activity parameters throughout disease course and will be shown at presentation.
Authors/Disclosures
Ashkan Vaziri, PhD (Biosensics LLC)
PRESENTER
Dr. Vaziri has received personal compensation for serving as an employee of Biosensics.
Leah G. Mann, PhD Dr. Mann has nothing to disclose.
Jose Casado (BioSensics LLC) Jose Casado has received personal compensation for serving as an employee of Biosensics.
Ram Kinker Mishra, PhD (Biosensics) Dr. Mishra has received personal compensation for serving as an employee of BioSensics LLC.
Adonay Nunes (Biosensics) Adonay Nunes has nothing to disclose.
Paula Trujillo Diaz Paula Trujillo Diaz has nothing to disclose.
Jessie Iregui Miss Iregui has nothing to disclose.
Amy Wynn, NP (Vanderbilt University Medical Center) Ms. Wynn has nothing to disclose.
Cynthia Wong Cynthia Wong has received personal compensation for serving as an employee of Alterity Therapeutics. An immediate family member of Cynthia Wong has received personal compensation for serving as an employee of RefleXion Medical. Cynthia Wong has stock in Teva. An immediate family member of Cynthia Wong has stock in 10x Genomics.
David A. Stamler, MD (Alterity Therapeutics) Dr. Stamler has received personal compensation for serving as an employee of Alterity Therapeutics. Dr. Stamler has stock in Alterity Therapeutics.
Daniel O. Claassen, MD, FAAN (Vanderbilt University Medical Center) Dr. Claassen has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Alterity. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Claassen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AskBio. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Michigan. Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cognition Therapeutics . Dr. Claassen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. The institution of Dr. Claassen has received research support from NIH. The institution of Dr. Claassen has received research support from CHDI. The institution of Dr. Claassen has received research support from HDSA. The institution of Dr. Claassen has received research support from Department of Defense. The institution of Dr. Claassen has received research support from CHDI.